Exact Sciences sees increase in ownership as Forsta AP Fonden adds new position during third quarter

☀️Trending News

Exact Sciences ($NASDAQ:EXAS) is a medical technology company that is focused on developing and commercializing diagnostic tests for the early detection and prevention of cancer. The company’s flagship product, Cologuard, is a non-invasive screening test for colorectal cancer that has been approved by the U.S. Food and Drug Administration (FDA). In addition to Cologuard, Exact Sciences also offers tests for other types of cancer, such as lung and pancreatic cancer. During the third quarter of this year, Exact Sciences saw an increase in ownership as Forsta AP Fonden, a Swedish state pension fund, added the company to its portfolio. It demonstrates confidence in the company’s potential for growth and success in the future. Forsta AP Fonden is known for its long-term investment approach and thorough research process, making their decision to add Exact Sciences to its portfolio even more significant. In addition to Forsta AP Fonden’s investment, Exact Sciences has also seen a steady increase in its share price over the past year. This is likely due to the success of Cologuard and other diagnostic tests, as well as the company’s partnerships and collaborations with major healthcare organizations.

As cancer screenings become increasingly important in the healthcare industry, Exact Sciences is well-positioned to continue its growth and success. The addition of Exact Sciences to Forsta AP Fonden’s portfolio also highlights the growing interest in the field of exact sciences, a term used to describe scientific disciplines that deal with precise measurements and quantifiable data. This includes fields such as mathematics, physics, chemistry, and biology. As technology advances and our understanding of these disciplines deepens, companies like Exact Sciences have the potential to make groundbreaking advancements in the detection and treatment of cancer and other diseases. It not only demonstrates confidence in the company’s potential for growth, but also highlights the importance and potential of exact sciences in the medical field. As Exact Sciences continues to make strides in the early detection and prevention of cancer, it is likely to attract even more attention and investment from major players in the market.

Share Price

This news comes as the company’s stock opened at $70.28 and closed at $68.89 on Thursday, down by 2.23% from the previous closing price of $70.46. The fund has a long-term investment approach and focuses on companies with strong financials and growth potential. With its advanced cancer screening and diagnostic tests, Exact Sciences has been making major strides in the medical industry. The company’s flagship product, Cologuard, is a non-invasive colorectal cancer screening test that has been gaining popularity in recent years. In addition to its successful products, Exact Sciences has also been expanding its partnerships and collaborations to further advance its research and development efforts.

This includes a recent collaboration with Pfizer to co-promote Cologuard in the United States and international markets. Such partnerships not only drive growth for the company but also showcase its credibility within the industry. As a major institutional investor, their decision to add a new position in the company is a positive sign for other investors. It also highlights the potential for continued growth and success for Exact Sciences in the coming years. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Exact Sciences. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Exact Sciences. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Exact Sciences. More…

Key Ratios Snapshot

Some of the financial key ratios for Exact Sciences are shown below. More…

Analysis

After conducting an in-depth analysis of EXACT SCIENCES‘s state of wellbeing, I can confidently say that the company is in a good position for growth. This is evident from their Star Chart which shows a strong performance in the growth category. However, I noticed some areas of weakness, particularly in the asset, dividend, and profitability categories. Based on our findings, EXACT SCIENCES falls under the category of ‘cheetah’ companies. This means that while they have achieved high revenue or earnings growth, they may be considered less stable due to their lower profitability. This could be a red flag for some investors, but it also presents an opportunity for those who are willing to take on a bit more risk. In my opinion, investors who are looking for a potentially high-growth company to add to their portfolio may be interested in EXACT SCIENCES. The company has shown strong growth potential and could be a valuable addition to a well-diversified portfolio. However, it’s important to note that while EXACT SCIENCES has a strong growth trajectory, it also has an intermediate health score of 4/10. This takes into consideration factors such as cashflows and debt. While this score may not be as high as some investors would like, it does indicate that the company may be able to safely ride out any financial crises without the risk of bankruptcy. Overall, EXACT SCIENCES shows promise for future growth and could be an attractive option for investors looking for potential high returns. However, it’s important to carefully consider the company’s weaknesses and assess one’s own risk tolerance before making any investment decisions. More…

Peers

The market for cancer diagnostics is highly competitive. Exact Sciences Corp, Inoviq Ltd, Myriad Genetics Inc, and BCAL Diagnostics Ltd are all major players in the industry. Each company has its own unique strengths and weaknesses, and the competition between them is fierce.

– Inoviq Ltd ($ASX:IIQ)

Inoviq Ltd has a market cap of 55.21M as of 2022. The company’s Return on Equity for the same year is -13.68%.

Inoviq Ltd is a technology company that focuses on developing innovative solutions for the mobile communications industry. The company’s products and services are designed to improve the efficiency and productivity of mobile operators and enterprises. Inoviq Ltd’s portfolio includes a wide range of products and services, such as mobile network optimization, mobile device management, and mobile application development.

– Myriad Genetics Inc ($NASDAQ:MYGN)

Myriad Genetics Incorporated is a biotechnology company that focuses on the development and commercialization of molecular diagnostic tests. The company’s tests are used for the early detection and risk assessment of various diseases, including cancer, cardiovascular disease, and Alzheimer’s disease. Myriad Genetics Incorporated is headquartered in Salt Lake City, Utah.

Summary

During the third quarter, Forsta AP Fonden made a new investment in Exact Sciences Co. This information was disclosed in their latest Form 13F report. This indicates that Forsta AP Fonden has confidence in the company and its potential for growth. It is also noteworthy that this investment was made during a time of economic uncertainty, which further showcases the confidence in Exact Sciences Co. This move may also encourage other investors to take notice of the company and potentially make similar investments. Overall, this news reflects positively on the potential of Exact Sciences Co. as an investment opportunity.